December 22, 2020 07:31 AM ESTUpdated December 28, 10:28 AM

FDA greenlights second Ebola treatment in three months, handing new OK to Ridgeback's Ebanga

Max Gelman

Senior Editor

A husband-and-wife biotech that licensed a Covid-19 antiviral before quickly partnering on it with Merck earlier this summer has a new approval in another highly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA greenlights second Ebola treatment in three months, handing new OK to Ridgeback's Ebanga

Max Gelman

Senior Editor

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

Bristol Myers CEO signals dealmaking will be a top priority in 2025

Roche CEO warns that tariffs could impact dealmaking

Roche takes steps to protect itself from tariffs, while Sanofi hangs back

Thermo Fisher buckles up for US-China trade war, budgets $2B to ease impact

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

FDA green­lights sec­ond Ebo­la treat­ment in three months, hand­ing new OK to Ridge­back­'s Eban­ga

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA greenlights second Ebola treatment in three months, handing new OK to Ridgeback's Ebanga